Akebia Therapeutics Target Price

As of the most recent data, AKBA shows a target price of $1. Scroll down for historical charts and peer comparison views.

If Akebia Therapeutics moved to the average analyst target of $1, shares would be roughly 15.0% higher than $0.87. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of Akebia Therapeutics's earnings trajectory.

Besides this target price page, Stockcircle has Akebia Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $1) with ownership activity and broader fundamentals.

Akebia Therapeutics's target price is $1; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.